IT IS CLAIMED:

1. A method of reducing liposome-induced complement activation upon *in vivo* administration of liposomes containing an entrapped therapeutic agent, comprising

providing liposomes comprised of a vesicle-forming lipid and between 1-10 mole percent of a neutral lipopolymer having the formula:

$$z \left\{ \begin{array}{c} O \\ O - C - R^1 \\ O - C - R^2 \end{array} \right\}$$

where each of R¹ and R² is an alkyl or alkenyl chain having between 8 and 24 carbon atoms;

$$n = 10 - 300$$
,

Z is selected from the group consisting of C_1 - C_3 alkoxy, C_1 - C_3 alkyl ether, n-methylamide, dimethylamide, methylcarbonate, dimethylcarbonate, carbamate, amide, n-methylacetamide, hydroxy, benzyloxy, carboxylic ester, C_1 - C_3 alkyl carbonate, and aryl carbonate; and L is selected from the group consisting of (i) -X-(C=O)-Y- CH_2 -, (ii) -X-(C=O)-, and (iii) -X- CH_2 -, where X and Y are independently selected from oxygen, NH, and a direct bond, with the proviso that when L is -X-(C=O)-, X is not NH;

and the remainder vesicle-forming lipids.

- 2. The method of claim 1, wherein X is oxygen and Y is nitrogen.
- 3. The method of claim 1, wherein L is a carbamate linkage, an ester linkage, or a carbonate linkage.
- 4. The method of claim 3, wherein L is $-O-(C=O)-NH-CH_2-$ (a carbamate linkage).

- 5. The method of claim 1, wherein Z is hydroxy or methoxy.
- 6. The method of claim 1, wherein said preparing includes preparing liposomes containing about 1 to 10 mole % of the neutral lipopolymer distearoyl (carbamate-linked) polyethylene glycol.
- 7. The method of claim 1, wherein said preparing includes preparing liposomes containing about 1 to 10 mole % of the neutral lipopolymer methoxy-polyethelene glycol 1,2 distearoyl glycerol.
- 8. The method of claim 1, wherein each of R¹ and R² is an unbranched alkyl or alkenyl chain having between 8 and 24 carbon atoms.
 - 9. The method of claim 8 wherein each of R^1 and R^2 is $C_{17}H_{35}$.
- 10. The method of claim 1, wherein *n* is between about 20 and about 115.
- 11. The method of claim 1, wherein the therapeutic drug is a chemotherapeutic agent.
- 12. The method of claim 11, wherein said chemotherapeutic agent is an anthracycline antiobiotic.
- 13. The method of claim 12, wherein said chemotherapeutic agent selected from the group consisting of doxorubicin, daunorubicin, epirubicin, and idarubicin.
- 14. The method of claim 11, wherein said chemotherapeutic agent is a platinum-containing compound.
- 15. The method of claim 14, wherein said platinum-containing antibiotic is cisplatin or a cisplatin analogue selected from the group consisting of carboplatin, ormaplatin, oxaliplatin, ((-)-(R)-2-aminomethylpyrrolidine (1,1-

cyclobutane dicarboxylato))platinum, zeniplatin, enloplatin, lobaplatin, (SP-4-3(R)-1,1-cyclobutane-dicarboxylato(2-)-(2-methyl-1,4-butanediamine-N,N'))platinum, nedaplatin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV).